Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00945438 | Study of the Influenza Vaccine (Split Virion, Inactivated) Northern Hemisphere 2009-2010 Formulation (Intradermal Route) | PHASE2 | COMPLETED | 131 | — | — | May 1, 2009 | Jul 1, 2009 | Jan 14, 2014 | 2 | France |
| Arm | Type | Description |
|---|---|---|
| Group 1 | EXPERIMENTAL | Participants aged 18 to 59 years at enrollment. |
| Group 2 | EXPERIMENTAL | Participants aged 60 years or older at enrollment. |
| Name | Type | Description |
|---|---|---|
| Influenza virus vaccine 2009-2010 formulation | BIOLOGICAL | 0.1 mL, Intradermal |
Inclusion Criteria: * Aged 18 to 59 years (i.e., to the day before the 60th birthday) or 60 years or older (from the day of the 60th birthday) on the day of inclusion * Provision of a signed informed consent * Able to attend all scheduled visits and comply with all trial procedures * For a woman of...